Estudios originales
Published on 24 de septiembre de 2024 | http://doi.org/10.5867/medwave.2024.08.2923
Fulvestrant in clinical practice: Effectiveness analysis in Uruguayan patients with HR+/HER2- breast cancer
Back to article
Median follow-up, overall survival and progression-free survival.
| Follow up | 14 | 0 to 163 | - | - | - |
| Overall survival | 16 | 15 to 18 | 36.0 | 7.0 | 1.2 |
| Progression-free survival | 6 | 6 to 7 | 13.1 | 4.3 | 1.3 |
Source: Prepared by the authors of this study.